(Reuters) -Gilead Sciences said on Friday its drug Trodelvy did not significantly improve progression-free survival in patients with the most common type of breast cancer when used as a first-line treatment, failing to meet the main goal of a late-stage study. Shares of the drugmaker fell 2% in early trading. The study compared Trodelvy with […]
Health
Gilead’s breast cancer drug fails to meet main goal of late-stage study
Audio By Carbonatix
(Reuters) -Gilead Sciences said on Friday its drug Trodelvy did not significantly improve progression-free survival in patients with the most common type of breast cancer when used as a first-line treatment, failing to meet the main goal of a late-stage study.
Shares of the drugmaker fell 2% in early trading.
The study compared Trodelvy with chemotherapy in 654 patients with advanced hormone receptor-positive, HER2-negative breast cancer, which makes up about 70% of cases, who have received prior hormone therapy.
An early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy, Gilead said.
The data for overall survival, however, was not mature at the time of the primary analysis, the company said, adding that the study will continue to assess this secondary goal.
Trodelvy is an antibody-drug conjugate, a class of drugs often called “guided missiles” for its ability to target cancer cells, and spare healthy cells.
Last month, the drug had lowered the risk of disease progression in certain patients with advanced triple-negative breast cancer (TNBC) when used as an initial treatment.
It is already approved for certain HR+/HER2-negative breast cancer patients who have received endocrine-based therapy and at least two additional systemic therapies after their cancer has spread.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Shailesh Kuber)